menu
    • menu

    Company profile for Vigeo Therapeutics

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vigeo was co-founded by Randolph Watnick, Ph.D., a pioneer in understanding the role of the tumor microenvironment in metastasis, and Jing Watnick, Ph.D., M.B.A., an accomplished research scientist and leader in biopharmaceutical development. To provide financing for the development of its science and its organization, Vigeo has partnered with Morningside Venture Investments, Ltd, a private equity and venture capital firm f...
    Vigeo was co-founded by Randolph Watnick, Ph.D., a pioneer in understanding the role of the tumor microenvironment in metastasis, and Jing Watnick, Ph.D., M.B.A., an accomplished research scientist and leader in biopharmaceutical development. To provide financing for the development of its science and its organization, Vigeo has partnered with Morningside Venture Investments, Ltd, a private equity and venture capital firm founded in 1992. Vigeo has secured Series A and B rounds of financing in 2015 and 2018, respectively.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vigeo TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    86 Sherman St. Cambridge, MA 02140
    Telephone
    Telephone
    617.945.0385
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vigeotherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vigeo-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vigeo Therapeutics Provides Update on VT1021 Treatment of GBM Expansion Patient
    Vigeo Therapeutics Provides Update on VT1021 Treatment of GBM Expansion Patient

    13 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vigeo-therapeutics-provides-clinical-update-on-vt1021-treatment-of-gbm-expansion-patient-301875920.html

    PR NEWSWIRE
    13 Jul 2023
    Share Share
    Vigeo will present Clinical & Immune Profiling Data from Ph I/II Expansion study
    Vigeo will present Clinical & Immune Profiling Data from Ph I/II Expansion study

    02 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vigeo-therapeutics-will-present-new-clinical-and-immune-profiling-data-from-ph-iii-expansion-study-in-gbm-patients-in-asco-poster-oral-session-301840335.html

    PR NEWSWIRE
    02 Jun 2023
    Share Share
    Vigeo New Immune Profiling and Biomarker Data Ph I/II Expansion study
    Vigeo New Immune Profiling and Biomarker Data Ph I/II Expansion study

    25 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vigeo-therapeutics-new-immune-profiling-and-biomarker-data-ph-iii-expansion-study-in-gbm-patients-301834951.html

    PR NEWSWIRE
    25 May 2023
    Share Share
    GCAR, Biohaven, Vigeo Commence Biohaven’s Troriluzole and Vigeo’S VT1021 Trial
    GCAR, Biohaven, Vigeo Commence Biohaven’s Troriluzole and Vigeo’S VT1021 Trial

    06 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220706005204/en

    BUSINESSWIRE
    06 Jul 2022
    Share Share
    Vigeo Therapeutics Announces New Phase 1/2 Data from VT1021 Study
    Vigeo Therapeutics Announces New Phase 1/2 Data from VT1021 Study

    16 Nov 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/vigeo-therapeutics-announces-new-phase-1-2-data-from-its-expansion-study-of-vt1021-at-the-society-of-neurooncology-s-2021-annual-meeting/?s=71

    BIOSPACE
    16 Nov 2021
    Share Share
    Vigeo Announces New Phase 1/2 Data from its Expansion Study of VT1021
    Vigeo Announces New Phase 1/2 Data from its Expansion Study of VT1021

    09 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/vigeo-therapeutics-announces-new-phase-12-data-from-its-expansion-study-of-vt1021-at-the-society-for-immunotherapy-of-cancers-2021-annual-meeting-301418785.html

    PRNEWSWIRE
    09 Nov 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search